Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020

Clin Appl Thromb Hemost. 2020 Jan-Dec:26:1076029620936350. doi: 10.1177/1076029620936350.

Abstract

This practical guidance, endorsed by the Brazilian Society of Thrombosis and Hemostasis and The Brazilian Society of Angiology and Vascular Surgery, the International Union of Angiology and the European Venous Forum, aims to provide physicians with clear guidance, based on current best evidence-based data, on clinical strategies to manage antithrombotic strategies in patients with coronavirus disease 2019.

Keywords: SARS-CoV-2; anticoagulants; antiplatelets; antithrombotic therapy; coronavirus disease 2019; thrombosis.

MeSH terms

  • Anticoagulants / therapeutic use
  • Betacoronavirus*
  • Biomarkers
  • COVID-19
  • Clinical Trials as Topic
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications*
  • Cytokine Release Syndrome / blood
  • Cytokine Release Syndrome / etiology
  • Disease Management
  • Endothelium, Vascular / physiopathology
  • Endothelium, Vascular / virology
  • Evidence-Based Medicine
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Lung Diseases / etiology
  • Lung Diseases / prevention & control
  • Pandemics*
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications*
  • Practice Guidelines as Topic*
  • Pulmonary Veins
  • SARS-CoV-2
  • Thrombophilia / etiology
  • Thrombophilia / therapy*
  • Thrombophlebitis / etiology
  • Thrombophlebitis / prevention & control
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control

Substances

  • Anticoagulants
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D